> Clinical scenario: Upon filling a prescription for oxycodone, a pharmacist reviews the patient\'s other medications: "In the Prescription Monitoring Program, I see that you're also being prescribed clonazepam by another physician. I wanted to make sure that you understand that combining pain medications, like oxycodone, and anxiety medications, like clonazepam, can increase your risk of drowsiness, sedation, and even overdose." The patient replies that she has been taking these medications for a long time and is not concerned. "I'm glad to hear that you're aware of the risks," the pharmacist says, "With your permission, I'm going to contact your prescribers, so we can monitor your risk and keep you safe."

EPIDEMIOLOGY
============

Drug overdose, driven largely by use of prescription opioids and heroin, is now the leading cause of accidental injury death in the United States, surpassing those caused by motor vehicle crashes (U.S. Food and Drug Administration, 2014; [@R86], [@R87]). From 2005 to 2013, annual opioid-related overdose deaths almost doubled, from 12,937 to 24,492 ([@R45]; [@R100]). The economic costs to society have been projected to surpass \$20 billion every year ([@R39]). This overdose crisis has been linked to the availability and potency of prescribed opioids ([@R67]; [@R65]; [@R15]; [@R20]). Whereas 71% of those who are at risk to misuse pain relievers report obtaining the medications from family and friends, 79% of those family and friends report being prescribed those medicines by their doctor ([@R82]). Both qualitative and epidemiologic studies have also demonstrated that heroin addiction is often preceded by prescription opioid misuse ([@R43]; [@R21]; [@R58]; [@R52]). Furthermore, fentanyl-related overdose fatalities have increased, involving fentanyl manufactured and distributed illicitly as part of the street drug market ([@R88]).

How Does an Opioid Overdose Occur?
----------------------------------

Opioid receptors are found throughout the nervous system, including the sections of the brainstem that control breathing. Stimulation of the receptors by opioids can cause euphoria, pain relief, sedation, and decreased respiration. High doses of opioids cause reduced sensitivity to oxygen and carbon dioxide levels, reducing respiratory drive and allowing tidal volume and respiratory rate to decrease. The resulting hypoxia can cause a loss of consciousness, and eventually, death. Signs of an overdose include decreases in respiratory rate, abnormal breathing sounds (snoring, gurgling, choking, etc.), decreased consciousness, miosis, and a blue/gray tinge of the skin, especially the lips and nail beds ([@R101]).

PREVENTION
==========

What are Common Risks for Opioid Overdose?
------------------------------------------

Medical providers and pharmacists should understand, explain to patients, and take actions to reduce overdose risk. The following should be considered when assessing a patient\'s risk.

First, *previous nonfatal overdose* is associated with future overdose ([@R48]). Second, *higher opioid doses*, such as daily doses higher than 50 morphine milli-equivalents ([@R31]), and *changes in dose or formulations* increase overdose risk; people who use heroin are thus frequently at risk due to unpredictable changes in substance purity from, for example, adulteration with fentanyl ([@R73]). Third, *polypharmacy and mixing substances* contribute to overdose risk, as opioid overdoses commonly involve other substances ([@R46], [@R46]). Psychoactive medications of particular concern include barbiturates, stimulants, and benzodiazepines ([@R41]; [@R105]; [@R44]). Other medications that can have synergistically central nervous system depressive effects include clonidine ([@R10]), promethazine ([@R77]; [@R56]), and gabapentin ([@R78]). Fourth, *socially isolated individuals* who use prescription opioids or heroin alone have little chance of being rescued. Isolation is also associated with depression, which is itself associated with overdose ([@R13]; [@R57]). Fifth, *chronic medical illnesses* involving organs, such as the lung, liver, kidney, and brain, primarily responsible for metabolizing substances and respiration, can compromise the body\'s ability to handle opioids ([@R105]). Sixth, *periods of abstinence*, such as periods of incarceration, hospitalization, and medical detoxification, cause reduced opioid tolerance and thus increased overdose risk. Accordingly, providers should educate and monitor patients restarting opioids or at risk of relapse ([@R103]; [@R81]; [@R66]).

Assessing a Patient\'s Overdose Risk
------------------------------------

Prescribers should assess overdose risk as part of a patient\'s history by the following means: reviewing medications and checking the Prescription Monitoring Program (PMP); reviewing medical and social history for above-mentioned risk factors; obtaining a focused substance use history; and obtaining an overdose history. The overdose history should determine if the patient has personally experienced an overdose ("Have you ever overdosed? What strategies do you use to prevent yourself from overdosing?"), witnessed an overdose ("Have you witnessed an overdose?"), or received training to prevent, recognize, and/or respond to one ("How would you respond to an overdose?"). Understanding the patient\'s experience and knowledge should guide the education provided.

Pharmacists should review medications, optimize medication safety, and provide patient education. This includes checking the PMP for psychoactive or sedating medications, addressing potential drug--drug interactions, ensuring that prescribers are aware of the patient\'s prescriptions, confirming understanding of the risks of opioids, providing overdose education, and filling naloxone prescriptions, or, when permitted, directly providing naloxone to the patient."The pharmacist calls the primary care doctor: "I saw your patient has prescriptions for both oxycodone and clonazepam and informed her of the risks of combining these medications" The doctor replies, "I was not aware of the clonazepam prescription. Who is the prescriber?" The pharmacist offers the other prescriber\'s name, which the doctor recognizes. "That makes sense. He\'s a psychiatrist that I refer my patients to. I'll discuss the risks with the patient at our appointment coming up.""

Strategies to Address Overdose
------------------------------

There are several existing strategies that address the Department of Health and Humans Services' priority areas of improving opioid-prescribing safety and access to medication-assisted treatment ([@R90]). Safe opioid-prescribing education has been supported by the Federal Drug Administration (FDA) and is mandated in some states like Massachusetts for prescribers to be relicensed (U.S. Food and Drug Administration, 2013). PMPs allow for prescribers and pharmacists to monitor what controlled substances a patient is filling at the pharmacy ([@R69]; [@R24]). Evidence of their effectiveness as overdose prevention tools is still mixed ([@R54]; [@R37]). Prescription drug disposal in many communities occurs at kiosks, often hosted at local police stations and other locations, with support from Drug Enforcement Administration (DEA) which holds nationwide "take-back" events ([@R35]; [@R92]). The DEA now also permits manufacturers, distributors, treatment programs, pharmacies, and healthcare facilities to become authorized collectors of prescription medications (U.S. Drug Enforcement Administration, 2014). Finally, medication for opioid use disorders, specifically methadone, buprenorphine, and naltrexone, is supported by evidence for increased abstinence and decreased opioid use ([@R74]; [@R60]; [@R49]; [@R61]). Methadone and buprenorphine treatment is also associated with decreased criminal activity ([@R8]; [@R30]; [@R55]; [@R11]; [@R79]), improved birth outcomes ([@R42]; [@R34]; [@R63]), and less overdose ([@R51]; [@R18]; [@R75]).""Your pharmacist contacted me about the risks of taking both clonazepam and oxycodone," the doctor informs the patient at their appointment. The patient does not understand the concern. The doctor explains that these medications have interactions that increase the chance of drowsiness and overdose, especially if she uses substances like alcohol or other drugs. "Do you ever feel drowsy or sedated from your medications?" The patient acknowledges one event when she took an extra oxycodone and clonazepam, after which her husband had trouble waking her up. The patient says that she now never takes anything more than what she is prescribed, and knows to call the doctor if she is struggling with pain, and her psychiatrist if she is struggling with her anxiety.""When the doctor asks how she stores her medication, she reports that she has started hiding pills from her son, "He got his wisdom teeth out and was given pain medication, and then he sprained his ankle and was given even more. I'm worried he has a drug problem and has switched over to heroin." According to the patient, on previous occasions after leaving treatment, he immediately relapsed, and she is now worried about him overdosing. The doctor reiterates the risk of overdose following a period of abstinence, and asks if she has a plan if her son should overdose. The patient says that she knows to call an ambulance and start rescue breathing, "But what else can I do?""

RESPONSE
========

What are Naloxone Rescue Kits?
------------------------------

Naloxone is an opioid antagonist that displaces opioids from brain receptors and restores breathing and consciousness. Naloxone is a prescription medication, but not a controlled substance. It usually takes 2 to 5 minutes to take effect and wears off after 30 to 90 minutes, so patients on long-acting opioids like methadone and extended-release oxycodone may have recurrent reduced respirations and overdose ([@R14]). Overdose responders should be encouraged to stay with the person overdosing after administration of naloxone. In cases of polysubstance or high potency fentanyl-related overdose, standard doses of naloxone may be insufficient, and thus rescue breathing and help from the emergency medical providers may be necessary to reverse the overdose. Administering naloxone may precipitate withdrawal symptoms in the victim.

There are multiple reasons to equip people in the community with a naloxone rescue kit. First, most opioid users do not use alone, and so have people around them that can intervene should an overdose occur ([@R5]; [@R72]). Second, risk factors for overdose have been identified, as discussed above. Third, the extent of hypoxic brain injury is time-dependent, so the sooner hypoxia is reversed, the better ([@R64]). Fourth, bystanders can be trained to recognize and respond effectively to overdoses with naloxone ([@R36]; [@R16]). Finally, fear of being arrested sometimes discourages bystanders from calling for medical assistance, and thus makes naloxone an important tool for people hesitant to call for help ([@R23]).

Naloxone rescue kits have been endorsed by numerous organizations, including the American Medical Association ([@R2]), American Society of Addiction Medicine ([@R4]), American Pharmacists Association ([@R3]), Substance Abuse and Mental Health Services Administration ([@R83]), World Health Organization ([@R104]), and United Nations Office on Drugs and Crime ([@R95]). In 2015, the American Heart Association published guidelines on opioid overdose response with naloxone in an update to their guidelines for cardiopulmonary resuscitation and emergency cardiovascular care ([@R53], Figure [1](#F1){ref-type="fig"}).

![American Heart Association Opioid-Associated Life-Threatening Emergency (Adult) Algorithm. Reprinted with permission. Circulation. 2015;132:S501-S518. © 2015 American Heart Association, Inc. (<http://circ.ahajournals.org/content/132/18_suppl_2/S501.long>).](adm-10-300-g001){#F1}

What Evidence Exists to Support Overdose Prevention Education and Naloxone Rescue Kits?
---------------------------------------------------------------------------------------

Overdose education and naloxone distribution programs have existed since the late 1990s as community-based initiatives based out of harm-reduction programs ([@R62]; [@R80]; [@R99]). Between 1996 and 2014, community organizations reported providing naloxone rescue kits to 152,283 laypersons and received reports of 26,463 overdose reversals ([@R100]).

Studies have shown feasibility of naloxone rescue kits in several different populations ([@R70]; [@R28]; [@R32]; [@R9]; [@R97]). Nonmedical bystanders can be effectively trained to respond to overdose ([@R36]; [@R85]; [@R96]). Some have expressed concern that naloxone availability would result in increased opioid use, but this has not been observed. Drug treatment rates have either stayed constant or increased ([@R76]; [@R29]). In several communities in which programs were implemented, overdose rates have decreased ([@R62]). In Massachusetts, where there was heterogeneous rollout of overdose prevention programs, communities with naloxone distributed to 1 to 100 people per 100,000 population saw opioid overdose death rates decrease by 27%, whereas in communities with naloxone distributed to over 100 people per 100,000 population, opioid overdose death rates declined by 46% ([@R98]). In a 2013 study, a best-case scenario determined a cost of \$438 per quality-adjusted life year (QALY) gained, whereas in the worst-case scenario, the cost was \$14,000 per QALY gained ([@R19]).Talking with Patients About Overdose Prevention and Response with NaloxoneMessages that providers can convey to patients:Only take opioids prescribed to you and as directed;If you are worried about your use of opioids, you can talk to me about it;If you are not taking opioids safely, I can help you find treatment;Make sure your prescribers and pharmacist are aware of all of your medications;Don't mix opioids with other drugs or alcohol;Store medication in a safe and secure place, and dispose of unused medication;Abstinence can change tolerance, so if you stop taking opioids, a lower dose may be needed upon restart;Teach friends and family how to respond to an overdose, including how to use naloxone and where you store it;Know how to recognize and respond to an overdose when you witness one.

"The doctor provides guidance for the patient and her son. "First, I'd like to monitor your medications more closely. I'm going to call your psychiatrist to discuss whether we should adjust your medications to something safer. I also recommend that you use a lock box, which you can get at the pharmacy, to secure your medications." The doctor then devises a plan for her son. "Ask him to consider a treatment program that includes a medication for opioid addiction, like methadone or buprenorphine---here is a card to contact the treatment hotline. Lastly, for both you and your son, I'm going to prescribe a naloxone rescue kit. The kit includes a medication called naloxone, and comes with instructions on how to recognize and respond to an overdose.""

Naloxone Rescue Kits at the Pharmacy: Prescribing, Stocking, Filling, and Billing
---------------------------------------------------------------------------------

Prescribing naloxone rescue kits should be a collaborative effort between prescribers and pharmacists. Both have the duty to recognize and mitigate overdose risk.

Most major wholesalers carry naloxone formulations (Table [1](#T1){ref-type="table"}). Outside of the inpatient setting, the most common methods of naloxone administration are intranasal and intramuscular. Evzio is an intramuscular formulation of naloxone in the form of an auto-injector ([@R7]).

To maintain its shelf life of 12 to 18 months, the product should only be drawn (for the intramuscular injection) or screwed (for the intranasal spray) into the syringe immediately before use. To maintain the shelf life, store at room temperature, avoid environments with fluctuating extreme temperatures like inside unattended automobiles, and away from direct light ([@R40]). Previously, the only option for intranasal naloxone was with the use of the intramuscular formulation with a luer-lock mucosal atomizer device (MAD), which must be stocked separately and does not have a national drug code. However, in November of 2015, the FDA approved a nasal naloxone spray, which requires no assembly ([@R93]). It is important to consider the patient\'s individual preferences and needs when choosing between naloxone formulations.

A growing number of public and private insurers are covering naloxone formulations. Pharmacists can determine coverage and prior authorization requirements. The cost of naloxone varies by formulation and distributor, but is around \$40 to \$150 for an intranasal regimen---less for the intramuscular regimen, more for the auto-injector---which may place them out of reach for many uninsured patients ([@R59]). Kaléo, the manufacturer of the auto-injector (Evzio), has a patient assistance program that limits the out-of-pocket cost for eligible patients ([@R33]). The MAD has an out-of-pocket cost of around \$5 each.

Three models exist for accessing naloxone rescue kits through a pharmacy ([@R38]). First, a prescriber can write a prescription for naloxone and the patient can fill it at the pharmacy. There, pharmacists can determine if naloxone is covered by the patient\'s insurance. Pharmacy staff should demonstrate the assembly and use of naloxone, and also provide further information on how to prevent, recognize, and respond to overdoses. Second, prescribers can write a prescription and, if permitted by state law, dispense the naloxone onsite. Third, pharmacies can provide naloxone directly to the patient via a pharmacist prescriber, or under a standing order, protocol, or collaborative practice agreement (CPA), explained in more detail below. In states that do not permit standing orders, protocols, or CPAs, pharmacists can contact the prescriber to have him or her call in or electronically send a prescription.

Variability exists across the country regarding availability and regulation of naloxone. Providers are encouraged to identify pharmacies in their areas that stock naloxone, and be aware of their state-specific laws surrounding naloxone prescribing."The patient visits the pharmacy to pick up her naloxone. The patient asks for some help to determine which is best for her. "I'd be happy to demonstrate," the pharmacist replies."

The Legal Environment for Naloxone Prescribing and Dispensing
-------------------------------------------------------------

The legal environment for naloxone prescribing is in general no different than that for any other prescription medication. Prescribers must ensure that prescriptions are issued in good faith, in the usual course of professional practice, and for a legitimate medical purpose ([@R1]). The prescription of naloxone for a patient at risk of overdose satisfies all 3 criteria ([@R12]).

Whereas intranasal use with a MAD is technically considered an off-label use of the intramuscular formulation, prescription of the medication for intranasal administration does not change liability risk. Depending on the setting, 20% to 80% of all prescriptions are written off-label, and the use of naloxone intranasally is a well-established practice ([@R68]; [@R47]; [@R102]). A recent review of relevant law discovered no instances in which a prescriber or dispenser was sued for prescribing or providing naloxone for community use ([@R26]). As with any medication, both prescriber and pharmacist should ensure that the patient understands the indications of the medication, possible side effects, and how to administer it in the event of an overdose.

As legislators have realized the need to increase naloxone access to laypersons, the majority of states have implemented laws and regulations to expand opportunities for naloxone prescription and distribution. Additionally, a number of states have passed laws that limit civil and criminal liability for prescribers, dispensers, and administrators, and also "Good Samaritans" who call for help in an overdose emergency, and the overdose victim ([@R23]; [@R22]).

### Third Party Prescribing

In recognition of the fact that the person who is at risk of overdose is often not the person that the clinician encounters (ie, often a friend or family member expresses concern to the prescriber about another person at risk), a number of state legislatures have taken action to permit prescribers to prescribe naloxone to people with whom they do not have a prescriber--patient relationship. This is termed "third party prescribing." In a state that allows for third party prescribing, the legal risk in doing so is no different than that if the prescriber were prescribing directly to the person at risk. Typically, the actual prescription will be written in the name of the person who has directly contacted the prescriber. As of September 2015, 37 states had passed laws permitting third party prescribing of naloxone. The question of whose insurance gets billed for third party prescriptions is an unresolved issue and policies currently differ from place to place.

### Enhanced pharmacy access

Some pharmacists practicing in federal agencies such as the Indian Health Service and Veterans Administration have prescribing authority, and several states have recently passed laws that permit some pharmacists to prescribe naloxone ([@R89]; [@R17]; [@R22]). Where the pharmacist is the prescriber, he or she is generally bound by the same requirements that apply to physicians and other prescribers.

A majority of states have passed laws that permit prescribers and pharmacists to establish CPAs or standing or protocol orders for naloxone. In these states, a pharmacist can dispense naloxone to any individual who meets criteria specified in the agreement or order. Rules and requirements are state-specific, though all states require a written agreement between prescriber and the pharmacy or pharmacist that sets out the terms. As of September 2015, 27 states permit pharmacy standing orders and 12 also permit naloxone to be distributed by laypersons acting under the authority of a prescriber at locations such as community-based organizations and drug treatment centers ([@R27]; [@R100]). In many states, standing orders are also used to authorize nonmedical first responders such as firefighters and police officers to possess and administer naloxone ([@R25], [@R25]).

### Immunity for Prescribers and Dispensers

Fear of legal consequences may still discourage some medical professionals from issuing naloxone prescriptions ([@R6]). To address this concern, 32 states have changed their laws to provide full or partial civil immunity to medical professionals who prescribe naloxone as permitted by law, whereas 30 provide such immunity to dispensers and 36 to the person who administers the medication in the event of an overdose. Most of these laws require that the medical professional not act negligently or recklessly in prescribing or dispensing. Because of these laws, prescribing or dispensing naloxone entails less risk in most states than prescribing or dispensing other medications.

### Good Samaritan Laws

Many people who use illicit drugs or medications other than prescribed may be wary of calling 911 in an overdose for fear of criminal sanctions. Overdose Good Samaritan laws, sometimes known as medical amnesty laws, are intended to encourage bystanders to call for help by providing limited criminal immunity to the person that makes the call, and also to the victim. This immunity is typically limited to relatively minor crimes, although in some states it extends to violations of probation or parole. For prescribers and pharmacists, it is important to let patients prescribed naloxone know of these laws, and reinforce the importance of not only administering naloxone, but also calling emergency medical response ([@R84]; [@R50]; [@R71]).

State-specific naloxone laws can be found at the Public Health Law Research Program\'s Law Atlas ([www.lawatlas.org](http://www.lawatlas.org/)).

CONCLUSIONS
===========

Prescribers and pharmacists should acknowledge and embrace their role in helping patients to prevent and respond to opioid overdoses. Clinical and legal environments have become more conducive to providing overdose prevention education and naloxone rescue kits. Engaging prescribers and pharmacists is crucial to addressing the overdose epidemic.

The Web site [www.prescribetoprevent.org](http://www.prescribetoprevent.org/) is a free online resource to help health care providers educate their patients to reduce overdose risk and provide naloxone rescue kits to patients. We would like to thank the contributors to the Web site.
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###### 

Naloxone Formulations and Features

                                         Injectable (and Nasal) Generic                                                                         Intranasal Branded                                                                                                           Injectable Generic                                                                                                               Auto-injector Branded
  -------------------------------------- ------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                                                                                                                                                                                                                                              
  FDA approval                           X (for IV, IM, SC)                                                                                     X                                                                                                                            X                                                                                                                                X
  Layperson experience                   X                                                                                                                                                                                                                                   X                                                                                                                                X
  Fragile; requires assembly             X                                                                                                                                                                                                                                   X                                                                                                                                
  Can titrate dose                       X                                                                                                                                                                                                                                   X                                                                                                                                
  Strength                               1 mg/mL                                                                                                4 mg/0.1 mL                                                                                                                  0.4 mg/mL or 4 mg/10 mL                                                                                                          0.4 mg/0.4 mL
  Cost per kit                           \$\$                                                                                                   \$\$                                                                                                                         \$                                                                                                                               \$\$\$
  Rx and quantity                        \#2, 2 mL Luer-Jet Luer-Lock needleless syringe plus \#2 mucosal atomizer devices (MAD-300)            \#1 two-pack of two 4-mg/0.1 mL intranasal devices                                                                           \#2 single-use 1-mL vials or \#1 10-mL multidose fliptop vial PLUS \#2 3 mL syringe with 23 to 25 gauge 1--1.5 inch IM needles   \#1 two-pack of two 0.4 mg/0.4 mL prefilled auto-injector devices
  Sig. (for suspected opioid overdose)   Spray 1 mL (1/2 of syringe) into each nostril. Repeat after 2 to 3 minutes if no or minimal response   Spray 0.1 mL into one nostril. Repeat with second device into other nostril after 2 to 3 minutes if no or minimal response   Inject 1 mL in shoulder or thigh. Repeat after 2 to 3 minutes if no or minimal response                                          Inject into outer thigh as directed by English voice-prompt system. Place black side firmly on outer thigh and depress and hold for 5 seconds. Repeat with second device in 2 to 3 minutes if no or minimal response
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